Maciej Banach: Novel Approaches for Statins for Doxorubicin-Induced Cardiotoxicity
Maciej Banach, Vice-Rector for the Collegium Medicum of KUL, shared a post on LinkedIn:
“Cardio oncology is now an area of critical interest, so important to our patients. Unfortunately, despite we may offer our patients very innovative and effective personalized anticancer treatment that may offer longer and longer PFS and OS, we sometimes forget to effectively treat cardiovascular risk factors and estabilished CVD.
Do you know that in cancer patients lipid profile is measured in less than 5% of patients (the Polish data that soon will be published). In the consequence lipid lowering therapy is also severly underused. And LLT, starting with statins that may have also anti-cancer properties and prevent against cancer treatment complications, may simply save and prolong life of patients living with a cancer.
Thus, I hope you find interesting our recent literature review on the novel approaches for statins for the management of the Doxorubicin-Induced Cardiotoxicity DIC that has been just released in the Cardiovascular Toxicology journal by Springer Nature. Soon we will present the first joint recommendations on LLT in cancer patients
Thanks Seyed Saeed Tamehri Zadeh and colleagues for amazing work on this and thanks Sebastian Szmit for important contribution.”
Title: Statins: Novel Approaches for the Management of Doxorubicin-Induced Cardiotoxicity – A Literature Review
Authors: Seyed Saeed TamehriZadeh, Mahla Khalaji, Mobina Tajdari, Helia Mavaddat, Sebastian Szmit, Naser-Aldin Lashgari, Nazanin Momeni Roudsari, Hamed Abbasi-Kashkoli, Maciej Banach, Amir Hossein Abdolghaffari
Cardio-Oncology in Focus: How Chemotherapy Can Harm Heart Health
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023